Evidence map›Paper›PMID 39676969›Full record

ArticleACS omega2024

Isoindolinedione-Benzamide Pyridinium Derivatives for Targeting Alzheimer's Disease.

Milad Noori, Minoo Khalili Ghomi, Navid Dastyafteh, Najmeh Oliyaei, Haleh Hamedifar, Shahrzad Javanshir, Nader Tanideh, Elahe Sattarinezhad, Fateme Sattari, Masoud Haghani and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Milad NooriPharmaceutical and Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran 16846-13114, Iran.
Minoo Khalili GhomiEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Navid DastyaftehPharmaceutical and Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran 16846-13114, Iran.
Najmeh OliyaeiStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
Haleh HamedifarCinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj 1461965381, Iran.
Shahrzad JavanshirPharmaceutical and Heterocyclic Chemistry Research Laboratory, Department of Chemistry, Iran University of Science and Technology, Tehran 16846-13114, Iran.ORCID https://orcid.org/0000-0002-3161-0456
Nader TanidehStem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
Elahe SattarinezhadDepartment of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
Fateme SattariStudent Research Committee, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
Masoud HaghaniDepartment of Physiology, The Medical School, Shiraz University of Medical Sciences, Shiraz 71348-14336, Iran.
Hojjat RahmaniDepartment of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran 1416634793, Iran.
Mir H HajimiriCinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj 1461965381, Iran.
Aida IrajiResearch Center for Traditional Medicine and History of Medicine, Department of Persian Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz 7134845794, Iran.ORCID https://orcid.org/0000-0002-8442-2205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An Isoindolinedione-benzamide pyridinium derivatives were designed through a structure-based strategy and synthesized as novel multifunctional anti-Alzheimer agents. The inhibitory activities of all 17 derivatives against acetylcholinesterase and butyrylcholinesterase were evaluated. Results exhibited that compound

Identifiers

PMID39676969
PMCPMC11635510

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.